Novartis (NVS,NOVN.SW) announced that its interleukin-17A inhibitor Cosentyx (secukinumab) met the primary and all secondary endpoints in the Phase III REPLENISH trial. The study evaluated Cosentyx in adults with polymyalgia rheumatica (PMR), a rare inflammatory rheumatic disease.
At Week 52, Cosentyx demonstrated statistically significant and clinically meaningful sustained remission compared to placebo. The trial also showed a reduction in annual cumulative steroid dose versus placebo through Week 52.
The safety profile of Cosentyx remained consistent with its established safety data. Polymyalgia rheumatica is characterized by bilateral pain in the neck, shoulders, or hips, along with morning stiffness and fatigue.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.